Mazdutide Dosage Guide: GLP-1 + Glucagon Dual Agonist Explained

Mazdutide

Mazdutide is an investigational dual incretin receptor agonist studied for metabolic regulation, appetite control, and weight management. It targets both GLP-1 and glucagon receptors, offering a unique mechanism compared to traditional GLP-1 compounds.

How It Works

GLP-1 Activation ↑ → Appetite ↓ → Gastric Emptying ↓ Glucagon Activation ↑ → Energy Expenditure ↑ → Fat Oxidation ↑

Mazdutide combines GLP-1 receptor activation (similar to semaglutide) with glucagon receptor activity, which may increase energy expenditure and fat metabolism. This dual mechanism is being studied for enhanced metabolic effects compared to single-pathway therapies.

Mazdutide Protocol

Standard Weekly Titration

Weeks 1–41 mg weekly

Weeks 5–82 mg weekly

Weeks 9–123–4 mg weekly

Advanced RangeUp to ~6 mg weekly

Frequency: Once weekly
Route: Subcutaneous injection
Cycle Length: Ongoing (titration-based use)

Real-World vs Clinical Use

Real-World Use

Typical Range1–4 mg weekly

GoalAppetite control + metabolic support

Clinical / Research Context

Studied Range1–6 mg weekly

FocusWeight loss + metabolic improvement

Reconstitution & Dosing

Typical Vial5 mg / 10 mg

Reconstitution2–3 mL bacteriostatic water

Example (10 mg vial + 2 mL)

Concentration = 5 mg/mL

1 unit = 50 mcg

When to Inject

• Once weekly on the same day
• Any time of day (consistent timing preferred)
• Can be taken with or without food
• Rotate injection sites

Monitoring During Use

• Appetite changes
• Body weight trends
• Energy levels
• Digestive tolerance

Mazdutide Guide →

Benefits

• Dual-action metabolic support
• Appetite reduction
• Potential increase in energy expenditure
• May support fat loss and glucose regulation

Potential Side Effects

• Nausea (most common during titration)
• Reduced appetite
• Fatigue during early adaptation
• Gastrointestinal discomfort

Important Notes

• Gradual titration improves tolerance
• Stay hydrated and maintain electrolyte balance
• Often compared to tirzepatide and retatrutide
• Individual response may vary

Important Disclaimer

Mazdutide is an investigational compound and is not FDA-approved. This content is for educational purposes only.

Browse All Peptides →